Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes
<p>Abstract</p> <p>Background</p> <p>Osteoprotegerin is a member of the tumor necrosis factor-related family and inhibits RANK stimulation of osteoclast formation as a soluble decoy receptor. The goal of this study was to determine the relationship of serum osteoprotege...
Main Authors: | Aoki Atsushi, Murata Miho, Asano Tomoko, Ikoma Aki, Sasaki Masami, Saito Tomoyuki, Otani Taeko, Jinbo Sachimi, Ikeda Nahoko, Kawakami Masanobu, Ishikawa San-e |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2013-01-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://www.cardiab.com/content/12/1/11 |
Similar Items
-
Relationship between serum osteoprotegerin and vascular calcifications in hemodialysis patients
by: Tarek Z. El Baz, et al.
Published: (2017-06-01) -
Serum Osteoprotegerin level and the extent of cardiovascular calcification in haemodialysis patients
by: Waleed Ammar, et al.
Published: (2014-03-01) -
Predictive value of osteoprotegerin for detecting coronary artery
calcification in symptomatic patients: correlation with extent of calcification detected by
multidetector computed tomography
by: Naser Aslanabadi, et al.
Published: (2016-02-01) -
Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet
by: Magnus Bäck, et al.
Published: (2019-01-01) -
Bone status and aortic calcifications in chondrocalcinosis patients
by: Vele Paulina, et al.
Published: (2020-04-01)